)
Visual
test
Piramal Pharma
Piramal Pharma (PPLPHARMA) investor relations material
Piramal Pharma Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary29 Jan, 2026
Executive summary
FY26 was challenging due to inventory destocking in a major on-patent product, slow early-stage CDMO order inflows from weak US biopharma funding, and regulatory delays in ex-US inhalation anesthesia launches.
Early signs of recovery are visible with increased RFPs and order inflows since October 2025, supported by improved US biopharma funding and M&A activity.
Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, were approved and reviewed by the Board and auditors, with results published as per regulatory requirements.
Acquisition of Kenalog, a branded injectable, for $35M upfront and up to $65M in contingent payments, aims to broaden the complex hospital generics (CHG) portfolio.
Financial highlights
Q3 FY26 consolidated revenue was ₹2,139.87 crore ($2,140M), down 3% YoY; nine-month revenue was ₹6,117.31 crore, down 4% YoY.
Q3 FY26 consolidated EBITDA was ₹239 crore (margin 11%), down 32% YoY; nine-month EBITDA was ₹628 crore (margin 10%), down 36% YoY.
Standalone net profit for Q3 FY26 was ₹128.91 crore, up from ₹118.80 crore YoY; consolidated net loss for Q3 FY26 was ₹136.19 crore, compared to a profit of ₹3.68 crore YoY.
BCH (consumer healthcare) sales grew 20% in Q3 and 16% over nine months, with power brands delivering 30% growth in Q3.
Q3 FY26 PAT before exceptional items was -₹95 crore; after exceptional items, -₹136 crore.
Outlook and guidance
Expecting sequential growth in Q4, historically the strongest quarter, but not year-over-year growth due to a large prior-year order.
Long-term growth prospects remain positive, with investments in capacity and capabilities to support recovery.
FY26 and 2030 guidance are reaffirmed, though recognized as a stretch.
The company continues to monitor regulatory changes and expects to account for further impacts from new labour codes as clarifications emerge.
Detail US CDMO onshoring drivers and RFP trends.
Kenalog: How does it drive CHG portfolio expansion?
Digwal RoW market strategy and ramp-up timeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- ENITY
Record 2025 results: 10% loan growth, 19.2% RoTE, SEK 1.4 dividend, strong outlook. - FODELIA
2025 net sales up 8.4%, strong Feelia growth, and higher sales and profitability expected in 2026. - ELMD
Revenue up 15.1% to $16.9M, net income up 44.9%, and strong margins with active buybacks. - BETOLAR
Record order intake, strong sales growth, and advances in low-carbon technology and solutions. - NORION
Net profit up 14% to SEK 1,438m, driven by Consumer and Payments growth and share buybacks. - BILI
Strong results with higher earnings, robust cash flow, and strategic expansion in key markets. - NCC
Record profits in core segments, robust cash flow, and positive outlook despite major impairment. - TMCV
Q3 FY26 delivered 17% revenue growth, 12.7% EBITDA margin, and rising market share. - DYVOX
Record revenue growth, improved profitability, and major acquisitions drive robust 2025 results. - PVRINOX
Record financials, reduced net debt, and a one-time expense highlight strong performance.
Next Piramal Pharma earnings date
Q4 25/2614 May, 2026
Piramal Pharma
Next Piramal Pharma earnings date
Q4 25/2614 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Piramal Pharma Limited is an India-based pharmaceutical company engaged in the development, manufacturing, and distribution of pharmaceutical products and services. The company operates through three main segments: Contract Development and Manufacturing (CDMO), Complex Hospital Generics, and Consumer Healthcare. It serves global pharmaceutical and biotechnology companies with services including drug development, active pharmaceutical ingredient (API) production, and sterile manufacturing. Piramal Pharma also markets over-the-counter products and hospital-use medications. The company is headquartered in Mumbai, India, and its shares are listed on the NSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage